Scientist II, Cell Line Engineering and CRISPR Screening jobs in United States
cer-icon
Apply on Employer Site
company-logo

Eikon Therapeutics · 10 hours ago

Scientist II, Cell Line Engineering and CRISPR Screening

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology to discover novel treatments for life-threatening diseases. They are seeking a motivated Scientist II, Cell Line Engineering and CRISPR Screening to support drug discovery programs, focusing on target validation and functional genomics efforts.

BiotechnologyHealth CareLife ScienceMedical
check
H1B Sponsor Likelynote

Responsibilities

Engineer and validate complex mammalian cell line models (including gene knock-in) tailored for target discovery and drug screening applications using Landing Pad, CRISPR/Cas9 and lentiviral approaches
Design and execute pooled and arrayed CRISPR knockout and activation screens in disease-relevant cell lines
Proficient in CRISPR/Cas9 gene editing including design of sgRNAs, lentiviral packaging, transduction, and validation of knockout, knock-in, or gene activation models
Develop robust high-throughput assays for phenotypic and functional characterization of engineered cell lines
Analyze CRISPR screen datasets using bioinformatics pipelines; integrate multi-omics data for mechanistic insights
Collaborate closely with medicinal chemistry, pharmacology, and computational biology teams to prioritize therapeutic targets and biomarkers
Drive continuous improvement of experimental protocols, data quality control, and automation strategies
Document findings comprehensively in lab notebooks, technical reports, and contribute to regulatory filings and patents as needed
Provide scientific mentorship and training to junior team members and interns

Qualification

CRISPR genome editingCell line engineeringData analysisMammalian cell cultureViral transduction methodsMolecular biology techniquesNGS library prepProblem-solving skillsEffective communication

Required

Postdoc fellowship; or Ph.D. in cell biology, molecular biology, genetics, bioengineering, or a related discipline plus 2 years of relevant experience; or Master's plus 12 years of relevant experience; or Bachelor's plus 14 years of relevant experience
3+ years of experience in CRISPR genome editing, cell line engineering, and large-scale functional screening in a biotech or pharmaceutical setting
Proficiency in mammalian cell culture, viral transduction methods, and molecular biology techniques
Strong data analysis skills using R, Python, or relevant bioinformatics tools to interpret CRISPR screening results
Experience with NGS library prep and understanding of sequencing data quality metrics
Demonstrated problem-solving skills with ability to work independently and in cross-functional teams
Effective written and verbal communication skills for interacting with internal stakeholders and external collaborators

Benefits

401k plan with company matching
Medical (premiums covered by Eikon at 95%), dental and vision insurance (premiums covered by Eikon at 100%)
Mental health and wellness benefits
Weeklong summer and winter holiday shutdowns
Generous paid time off and holiday policies
Life/AD&D Insurance (premiums covered by Eikon at 100%) and optional supplemental employee-paid life/AD&D policies
Enhanced parental leave benefit
Daily subsidized lunch program when on-site

Company

Eikon Therapeutics

twittertwittertwitter
company-logo
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

H1B Sponsorship

Eikon Therapeutics has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (17)
2023 (7)
2022 (3)
2021 (1)

Funding

Current Stage
Late Stage
Total Funding
$1.12B
Key Investors
The Column Group
2025-02-26Series D· $350.7M
2023-06-01Series C· $106M
2022-01-06Series B· $518M

Leadership Team

leader-logo
Roger Perlmutter
Chairman, President, and CEO
linkedin
leader-logo
Michael Klobuchar
Chief Operating Officer
linkedin
Company data provided by crunchbase